Figure 5.
Figure 5. Western blot analyses. (A) Western blot analysis showing BRCA1 and BCR-ABL expression in different MO7e cells. Cell extracts (50 μg) were subjected to Western blot analysis using anti-BRCA1, anti–c-ABL, and antiphosphotyrosine (lane 1, MO7e MIGR EGFP; lane 2, MO7e MIGR BCR-ABL-IRES-eGFP; lane 3, MO7e MIGR BCR-ABL/1172-IRES-eGFP). (B) Western blot analysis showing the effects of STI571 (C-ABL tyrosine kinase inhibitor) in UT-7 cell clones. Parental UT-7/P and BCR-ABL–expressing UT-7/9 cells were grown in rhGM-CSF and exposed to STI571 5 μM for 24 hours. Whole-cell extracts were subjected to Western blot analysis using anti-BRCA1, anti–c-ABL, antiphosphotyrosine, and anti–β-actin (lane 1, UT-7/P control; lane 2, UT-7/P + STI571; lane 3, UT-7/9 control; lane 4, UT-7/9 + STI571).

Western blot analyses. (A) Western blot analysis showing BRCA1 and BCR-ABL expression in different MO7e cells. Cell extracts (50 μg) were subjected to Western blot analysis using anti-BRCA1, anti–c-ABL, and antiphosphotyrosine (lane 1, MO7e MIGR EGFP; lane 2, MO7e MIGR BCR-ABL-IRES-eGFP; lane 3, MO7e MIGR BCR-ABL/1172-IRES-eGFP). (B) Western blot analysis showing the effects of STI571 (C-ABL tyrosine kinase inhibitor) in UT-7 cell clones. Parental UT-7/P and BCR-ABL–expressing UT-7/9 cells were grown in rhGM-CSF and exposed to STI571 5 μM for 24 hours. Whole-cell extracts were subjected to Western blot analysis using anti-BRCA1, anti–c-ABL, antiphosphotyrosine, and anti–β-actin (lane 1, UT-7/P control; lane 2, UT-7/P + STI571; lane 3, UT-7/9 control; lane 4, UT-7/9 + STI571).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal